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DOI 10.1016/j.neuron.2007.02.001When Alois Alzheimer in 1906 pre-
sented the first case report on the
neurodegenerative disorder that now
(in)famously bears his name, Alz-
heimer’s disease (AD) was thought to
be a rare, noninherited, and sporadic
condition. Now, a hundred years later,
it has reached epidemic proportions,
thereby rapidly transforming itself into
a major socioeconomic problem. The
main reason for this lies in the increase
in average human life expectancy
in Western countries, from approxi-
mately 47 years in 1906 to 77 years
today. Caused by this shift in longevity,
the number of late-onset cases, i.e.,
those that clinically manifest them-
selves beyond the age of 65, has by
far eclipsed the much rarer and often
familial early-onset cases.
When Alzheimer first examined the
brain of his ‘‘index’’ patient to search
for a morphological cause for the pro-
found dementia and aberrant behavior
that Auguste D. had displayed during
the last years of her life, he observed
and documented the ‘‘hallmark’’ histo-
pathological changes that to this day
form the pillars of postmortem diagno-
sis of AD: (1) a prominent accumula-
tion of amyloid plaques, which, as we
now know, are triggered by the aggre-
gation of the amyloid b protein (Ab),
a cleavage product of the amyloid
precursor protein (APP), and (2) the
neurofibrillary tangles, which consist
mainly of aggregated forms of the
microtubule stabilizing protein tau.
Over 70 years later, in 1984, George
Glenner and colleagues eventually pu-
rified and sequenced the Ab peptide.
In their initial description, they noted
that this protein ‘‘may provide a diag-
nostic test for Alzheimer’s disease
and a means to understand its patho-
genesis’’ (Glenner and Wong, 1984).
Besides setting the stage for the ‘‘amy-loid hypothesis,’’ Glenner’s sequence
of the Ab peptide opened the door to
the cloning of the precursor protein
from which it is derived, which in turn
soon led to the identification of the first
dominant mutation in APP as a cause
of familial early-onset AD (Goate et al.,
1991). Further support for the pivotal
role of Ab in the pathogenesis of AD
came from the genetic and biochemi-
cal identification of two intramembra-
neous proteases that where found to
mediate the ultimate cleavage step
that releases the Ab peptide from APP.
Numerous missense mutations have
also been found in these proteases,
now known as presenilins 1 and 2,
that cause vicious and high-penetrant
forms of familial early-onset AD (re-
viewed in Selkoe and Podlisny, 2002).
Thus, APP and the presenilins form
a classic substrate-enzyme relation-
ship that is responsible for producing
the peptide that makes up the patho-
logic amyloid deposits; taken to-
gether, this genetic and biochemical
evidence overwhelmingly points to
a pivotal function of the Ab-generating
machinery that must be part of the dis-
ease-causing mechanism. However,
most AD cases are of the nonfamilial
kind that manifests itself late in life,
and these are typically not caused by
or associated with mutations in the
APP and presenilin genes. Indeed,
the most powerful and undisputed
‘‘late-onset AD (LOAD) gene’’ is apoli-
poprotein E (ApoE), specifically the
presence of the common 34 isoform,
which increases the relative risk in
a dose-dependent manner (Corder
et al., 1993). Yet, ApoE has no obvious
structural or functional relationship
with the early-onset genes or with the
Ab-generating machinery, and the
mechanisms by which ApoE4, either
directly or indirectly (reviewed in HerzNeuron 53, Feand Chen, 2006; Mahley et al., 2006),
promotes the disease process have
not been unequivocally resolved.
Numerous other AD susceptibility
genes and quantitative trait loci (Kehoe
et al., 1999) have been proposed over
the last decade (reviewed in Bertram
et al., 2007), but their relative contribu-
tions and significance have frequently
come under debate, and few of these
candidates have known functions that
would implicate them directly in Ab
generation. Thishas revealed,however,
that AD, and especially the late-onset
form, is in fact a highly complex genetic
syndrome for which we still lack suffi-
cient understanding of the underlying
molecular mechanisms that alter neu-
ronal cell biology andcause theprema-
ture loss of synapses and neurons.
This considerable genetic complex-
ity, combined with the imperfect his-
topathological correlation of plaque
deposition on one hand and neuronal
loss and dementia on the other, has
raised a ‘‘chicken and egg’’ question
and fueled a—sometimes furious—
debate in the field: are the plaques
themselves primarily responsible for
the manifestation of the disease or is
it the disruption of more fundamental
cellular functions that, when impaired,
send the neuron on its way to death,
while promoting plaque formation in
the process? Clearly, APP processing
and Ab generation must play a crucial
part in this, since many other neurode-
generative diseases do not exhibit the
distinct AD amyloid pathology, so im-
pending neuronal demise alone does
not suffice.
Progress in our understanding of
this central question has been ham-
pered by our lack of knowledge of
what the physiological functions of
APP actually are, and this has led sev-
eral groups to consider alternativebruary 15, 2007 ª2007 Elsevier Inc. 477
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might act on neurons. Some have
recently begun to focus on possible
direct effects of Ab on synaptic neuro-
transmission and glutamate receptor
activity (Walsh et al., 2002; Kamenetz
et al., 2003). The findings that are
now emerging from these studies
reveal novel mechanisms by which
Ab might directly control synaptic
plasticity, with potential conse-
quences for synaptic stability and sur-
vival. These results also point toward
exciting, new, and plausible mecha-
nisms by which the effect of ApoE,
possibly acting through ApoE recep-
tor-mediated control of NMDA recep-
tor activity, might converge with the
signal input provided by the Ab pep-
tide directly at the level of the synapse
(reviewed in Herz and Chen, 2006).
Another potential mechanism by
which APP might affect neuronal func-
tions is through its intracellular domain
(ICD). There are threeAPP familymem-
bers in mammalian species, but only
APP produces the Ab peptide. Mice
lacking all three genes show greatly
reduced viability and exhibit brain de-
velopmental abnormalities that resem-
ble lissencephaly (Herms et al., 2004),
suggesting that the APP family has
fundamental roles in brain develop-
ment, potentially involving the regu-
lation of cell adhesion. Interestingly,
mice lacking FE65 and FE65-L1, two
members of a family of three cytoplas-
mic scaffolding proteins, show a strik-
ingly similar phenotype (Guenette
et al., 2006). Furthermore, the loss-
of-function phenotypes of apl-1 and
feh-1, the sole orthologs of the APP
and FE65 familymembers in the simple
nematode Caenorhabditis elegans,
also mirror each other, suggesting
that the intracellular domain (ICD) of
APP, to which the FE65 proteins bind,
may form a physiologically important
complex with FE65 family members.
Release of the ICD is necessarily
coupled to the generation of the Ab
peptide, since the ultimate cleavage
of APPbyg-secretase, i.e., a presenilin
containing complex, results in an equi-
molar production of either peptide.
Moreover, presenilins not only cleave
APP, but also a series of other mem-
brane proteins, most notably Notch,478 Neuron 53, February 15, 2007 ª2007for which an essential role of its ICD
in the regulation of gene transcription
had been well established. These
insights prompted Cao and Su¨dhof
(Cao and Su¨dhof, 2001) to investigate,
whether the ICD of APP (AICD) may
also be involved in transcriptional reg-
ulation. Using reporter assays, they
found indeed that release of the AICD
from the plasma membrane could
stimulate reporter gene activation.
This was dependent upon the activa-
tion and release of FE65 at the plasma
membrane and on the recruitment of
Tip60, a transcriptional activator, by
this scaffolding protein. Glass, Rosen-
feld, and colleagues subsequently
suggested that the AICD/FE65/Tip60
complex might be involved in the regu-
lation of NF-kB target genes, through
exchange of a nuclear receptor core-
pressor complex (Baek et al., 2002).
Building on these initial reports, Par-
dossi-Piquard et al. (Pardossi-Piquard
et al., 2005) searched for target genes
that might be controlled by presenilin-
mediated cleavage of APP family
members and AICD release. In their
study, published in Neuron in 2005,
they focused on neprilysin, an Ab-de-
grading enzyme. The work was based
on the rationale that this protease
might be a plausible target for AICD/
FE65/Tip60-mediated transcriptional
regulation, since such an intrinsic feed-
back mechanism would automatically
ensure that Ab concentrations would
be maintained within narrow parame-
ters, thereby preventing Ab-mediated
cellular toxicity and amyloid formation.
The findings of the Pardossi-Piquard
et al. study have recently been chal-
lenged. A study conducted indepen-
dently in Bart de Strooper’s laboratory
(Hebert et al., 2006), did not find con-
vincing evidence for an AICD-depen-
dent mechanism by which the expres-
sion of a number of previously
suggested target genes, including ne-
prilysin, might be transcriptionally reg-
ulated. These conclusions are echoed
in the Correspondence by Chen and
Selkoe (this issue of Neuron), who
also raise questions about the data in
the original Pardossi-Piquard et al.
study and about the evidence support-
ing a presenilin and AICD-dependent
feedback mechanism that controlsElsevier Inc.the degradation of Ab through neprily-
sin. In their Response, Pardossi-
Piquard and colleagues (this issue of
Neuron) point to a series of findings
presented by Chen and Selkoe that
lend support to several important ele-
ments published in their initial report,
most notably the virtual absence of ne-
prilysin expression in presenilin 1 and 2
double-deficient cells. This remarkable
reduction of expression was also ob-
served in the absence of APP and
APLP-2 (Pardossi-Piquard et al.,
2005). In further support of the conclu-
sions they now also show preliminary
data from FE65/AICD double-trans-
genic mice that reveal significantly in-
creased neprilysin expression in brain.
What might be the reasons for such
seemingly diametrically opposite con-
clusions and conflicting results? Part
of this discrepancy might be explain-
able by differences in experimental
approaches and clonal variations or
origin of the cell lines that were used
by the different groups, as well as
diverging opinions about the signifi-
cance and interpretation of the
strength of specific pieces of experi-
mental evidence. However, the con-
ceptual and biomedical importance of
the mechanism Pardossi-Piquard and
colleagues have proposed will ensure
that the current controversy will be re-
solved quickly and in due course
through independent work of other
laboratories that will build on these
findings and conclusions.
Some things nevertheless are cer-
tain: (1) our mechanistic understand-
ing of the pathogenesis of AD is rudi-
mentary at best and much remains to
be discovered, (2) this field is not likely
to get boring tomorrow, and (3) even
now, over 90 years after his death,
Alois Alzheimer continues to watch out
that he will not be forgotten for years
to come.
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Pardossi-Piquard et al. (2005) recently
reported that the processing of APP
by the presenilin/g-secretase complex
to release the APP intracellular domain
(AICD) allows the latter to upregulate
the cellular expression of neprilysin.
The authors emphasized the biological
eleganceof thisnovel feedbackmecha-
nism in that a by-product (AICD) of the-
generation of amyloid b protein (Ab)
increases the levels of a protease
(neprilysin) that can then degrade Ab.
Here,wereport thatexperimentssimilar
to those of Pardossi-Piquard et al. did
not provide evidence that neprilysin
levels and activity are regulated by pre-
senilin-mediated processing of APP.
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expression as reported (Pardossi-
Piquard et al., 2005),mouseembryonic
stem cells genetically devoid of both
PS1andPS2 (BD8cells)were analyzed
by Western blotting (see Methods in
the Supplemental Data available
online). Cells were harvested in Tris
buffer containing either no detergent,
0.5% Triton X-100, or 1% NP40 and
blotted for neprilysin, APP C-terminal
fragments (CTFs), and GAPDH. The
lack of PS expression resulted in no
significant reduction in neprilysin levels
in cells harvested in either Tris buffer
or Tris-1% NP40 buffer compared to
identically prepared wt embryonic
stem cells (PBD8) (Figure 1A). In cells
harvested in Tris-0.5% Triton buffer,
we observed either a modest (Fig-
ure 1A) or no (Figure S1A) reduction in
neprilysin levels. To determinewhether
introduction of presenilin could rescue
this variable andmodest decrease, the
BD8 cells were transiently transfected
with PS1, PS2, or both. Transfection
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of PS resulted in the rescue of g-secre-
tase complex formation (PS endo-
proteolysis and enhanced nicastrin
maturation) and activity (reduction in
the elevated APP CTFs) in the BD8
cells (Figure 1B) (Chen et al., 2003;
Kimberly et al., 2002; Leem et al.,
2002). However, neprilysin levels were
unchanged (Figure 1B). When quanti-
fied, neprilysin levels (versus control)
were 93.7% ± 0.2% (SEM), 105.7% ±
1.1%, and 98.6% ± 18.3% for cells
transfected with PS1, PS2, or both,
respectively (p > 0.05 in all cases)
(Figure S1B).
Next, we examined primary mouse
embryonic fibroblasts (MEFs) cultured
from mice genetically lacking PS1,
PS2, or both, using the same source
as those analyzed by Pardossi-Piquard
et al. (Herreman et al., 2003). Neprilysin
levels were reduced in PS dKO cells
ascompared towt (Figure1C).Because
PS1 confers the predominant PS activ-
ity found in g-secretase, it would be
bruary 15, 2007 ª2007 Elsevier Inc. 479
